eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
1/2019
vol. 44
 
Share:
Send email
Share:
abstract:
Review paper

Investigations of cellular immunity in juvenile idiopathic arthritis

Lucia Maria Sur
1
,
Genel Sur
2
,
Gabriel Samasca
3
,
Iulia Lupan
4

  1. Department of Paediatrics I, “Iuliu Haţieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
  2. Department of Paediatrics II, “Iuliu Haţieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
  3. Department of Immunology, “Iuliu Haţieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
  4. Department of Molecular Biology, “Babes-Bolyai” University, Cluj-Napoca, Romania
(Centr Eur J Immunol 2019; 44 (1): 92-96)
DOI: https://doi.org/10.5114/ceji.2019.83615
Online publish date: 2019/03/14
View full text Get citation
 
PlumX metrics:
The following was emphasised in an informative, educational issued on the American College of Rheumatology website in April 2017: “About one child in every 1000 develops some type of chronic arthritis. These disorders can affect children at any age, although rarely in the first six months of life. It is estimated that around 300,000 children in the United States have been diagnosed with the condition”.Therefore, knowledge of immunological investigations in patients with juvenile idiopathic arthritis is important for finding new treatment pathways. Our aim was to assess the immunological investigations and immune system implications in juvenile idiopathic arthritis. We will discuss: a) the specifically targeted proteins – the citrullinated peptide antibodies; b) non-specifically targeted proteins – heat-shock proteins (anti-HSP60, -65, and -70 antibodies), CLEC16A, inflammasomes, and phagocyte-derived S100; c) interleukins – IL-1, IL-6, IL-10, IL-17, and IL-18; d) innate immunity – macrophage activation syndrome, natural killer cells, complement activity, and immune complexes; and e) therapeutic targets – monoclonal antibodies, JAK inhibitors, and intravenous immune globulin.
keywords:

juvenile idiopathic arthritis, immunopathology, immunological targets
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.